Folks, I have used doxycycline off and on for years. Of course you can not use it on a regular basis; I use it about every 3 to 4 months for a weak or two at a time.
As some of you know I do the shotgun approach (my invention) to fighting cancer. I will do about anything that might help, as long as I don't do my body harm. Works for me. Still psa under .01 after 16 years, gleason 9, in lymph nodes. Never had a rise in psa. No brag, just thankful.
P. S. Not intended for advice. I hope I have not broken any rules by posting a research project from Pub Med.
Anticancer Drugs. 2003 Nov;14(10):773-8.
Doxycycline and other tetracyclines in the treatment of bone metastasis.
Saikali Z, Singh G.
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell lines of various tumor origins. In addition, tetracyclines and chemically modified tetracyclines inhibit the activity of several matrix metalloproteinases (MMPs). Given the importance of these enzymes in tumor cell invasion and metastatic ability, the potential use of tetracyclines in cancer therapy needed to be investigated. Col-3, a chemically modified tetracycline, is now the subject of clinical trials in cancer patients. However, the potential of tetracyclines in cancer therapy takes on an added dimension in the bone. MMPs have been shown to be important mediators of metastasis formation in the bone, contributing largely to the morbidity of breast cancer and prostate cancer patients. The natural osteotropism of tetracyclines would allow them to be highly effective in the inhibition of MMPs produced by osteoclasts or tumor cells in the bone. This hypothesis has now been confirmed by experimental evidence showing that doxycycline reduces tumor burden in a mouse model of breast cancer-derived osteolytic bone metastasis. This effect is likely due to a combination of multiple roles of doxycycline, including MMP inhibition and a negative effect on osteoclast differentiation and survival. These encouraging results have now paved the way for an ongoing trial of doxycycline in early combination therapy for breast cancer and prostate cancer patients.
PMID: 14597870 [PubMed - indexed for MEDLINE]
Publication Types, MeSH Terms, SubstancesPublication Types:
Research Support, Non-U.S. Gov't
Antibiotics, Antineoplastic/therapeutic use
Bone Neoplasms/drug therapy*
Cell Line, Tumor
Clinical Trials as Topic
Matrix Metalloproteinases/antagonists & inhibitors
LinkOut - more resourcesFull Text Sources:
Lippincott Williams & Wilkins
Ovid Technologies, Inc.
Swets Information Services
Bone Cancer - MedlinePlus Health Information
Molecular Biology Databases:
DOXYCYCLINE - HSDB
Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. [Invasion Metastasis. 1997] Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
Duivenvoorden WC, Hirte HW, Singh G.
Invasion Metastasis. 1997; 17(6):312-22. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. [Int J Cancer. 2002] Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. [Cancer Res. 2002] Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC, Popović SV, Lhoták S, Seidlitz E, Hirte HW, Tozer RG, Singh G.
Cancer Res. 2002 Mar 15; 62(6):1588-91. Review MMP inhibition in prostate cancer. [Ann N Y Acad Sci. 1999] Review MMP inhibition in prostate cancer.
Ann N Y Acad Sci. 1999 Jun 30; 878:271-89. Review Development of matrix metalloproteinase inhibitors in cancer therapy. [J Natl Cancer Inst. 2001] Review Development of matrix metalloproteinase inhibitors in cancer therapy.
Hidalgo M, Eckhardt SG.
J Natl Cancer Inst. 2001 Feb 7; 93(3):178-93. See reviews...
Cited by 3 PubMed Central articles
Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria. [Cancer Cell Int. 2010] Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria.
Sagar J, Sales K, Taanman JW, Dijk S, Winslet M.
Cancer Cell Int. 2010 Sep 6; 10:31. Epub 2010 Sep 6.Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer? [World J Surg Oncol. 2009] Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?
Sagar J, Sales K, Dijk S, Taanman J, Seifalian A, Winslet M.
World J Surg Oncol. 2009 Jan 6; 7:2. Epub 2009 Jan 6.Review MMPs as therapeutic targets--still a viable option? [Semin Cell Dev Biol. 2008] Review MMPs as therapeutic targets--still a viable option?
Semin Cell Dev Biol. 2008 Feb; 19(1):61-8. Epub 2007 Jul 6.All links from this record
Related Citations Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.Compound (MeSH Keyword) PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.Substance (MeSH Keyword) PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.Cited in PMC Full-text articles in the PubMed Central Database that cite the current articles.Recent activity
Clear Turn Off Turn On
Doxycycline and other tetracyclines in the treatment of bone metastasis. Doxycycline and other tetracyclines in the treatment of bone metastasis.
Anticancer Drugs. 2003 Nov ;14(10):773-8.PubMedMonensin influences basal and human growth hormone-releasing hormone 44-induced ... Monensin influences basal and human growth hormone-releasing hormone 44-induced release of stored and new rat growth hormone and prolactin.
Mol Cell Endocrinol. 1989 Apr ;62(2):253-62.PubMedYour browsing activity is empty.
Activity recording is turned off.
Turn recording back on